Patients with hypersensitivity reaction to carboplatin (ovarian cancer, fallopian tubal cancer, primary peritneal cancer)
Conditions
Interventions
Patients were treated with paclitaxeal followed by cisplatin weekly. Paclitaxeal dose was fixed at 80mg/m2. Cisplatin dose was tailored to individualized maximum repeatable dose. Stating dose of cispl
Sponsors
SchooMedicine, Chiba university
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Patients with a histological diagnosis of ovarian cancer (including fallopian tube, or primary peritoneal carcinoma) 2)Prior one regimens chemotherapy is required. Patients had hypersensitivity reactions to carboplatin. 3)Patients have at least one measurable disease. 4)No chemotherapy within 2 weeks prior to the registration 5)Patients who are 20 years old or older and younger than 79 years old at the enrollment 6)Performance status:ECOG 0-2 7)Adequate bone marrow, renal, and hepatic function 8)Patients who are expected to survive more than 3 months. 9)Patients who have signed an approved informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients who have a history of hypersensitivity to paclitaxeal. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypersensitivity reactions to cisplatin | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events Progression free survival response rate (disease control rate) overall survival tolerability patients QOL | — |
Countries
Japan
Contacts
Public ContactShinichi Tate, M.D.
Chiba university Hospital Gynecology
Outcome results
None listed